HopeStage
Back to all studies
Active Not RecruitingNCT03932136

Sulforaphane and risk of psychosis in people at clinical high risk

About this titleRead the official source — NCT03932136
Placebo comparisonAges 15–45ChinaSchizophrenia
The study in practice

Understand this study

Who could participate?

Listed age limits: 15 years to 45 years.

Listed locations
Guangzhou and 8 more locationsSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: July 14, 2019
Recruitment status
Active Not Recruiting
Enrollment listed in the registry
300
Sponsor
Shanghai Jiao Tong University School of Medicine
Sponsor type
University
Study type
Drug
Intervention type
Combination product, Dietary supplement
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
China
Age range
From 15 Years to 45 Years
Official registry ID
NCT03932136
Official title
Show the full official title

Decreasing Risk of Psychosis by Sulforaphane: Study Protocol for a Randomized, Double-blind, Placebo-controlled, Clinical Multicenter Trial (DROPS Trial)

Recruitment & locations

Not recruiting

Guangzhou · Zhengzhou · Changsha

4 more locations
  • Suzhou
  • Shanghai
  • Shenzhen
  • Tianjin

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Shanghai Jiao Tong University School of Medicine, a university.

Who can participate?

Listed age limits: 15 years to 45 years.

Is this study still recruiting?

The registry lists this study as active, but no longer recruiting.

Want to explore more studies?

Explore studies